Italia markets open in 1 hour 37 minutes

Biocartis Group NV (0R72.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
1,7340+0,0143 (+0,83%)
Alla chiusura: 05:40PM BST
Schermo intero
Chiusura precedente1,7197
Aperto1,7197
DenaroN/D x N/D
LetteraN/D x N/D
Min-Max giorno1,7200 - 1,7200
Intervallo di 52 settimane1,7200 - 1,7200
VolumeN/D
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)1,52
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Press release Biocartis Group NV: Biocartis To Publish 2022 Annual Report on 11 April 2023

    PRESS RELEASE - REGULATED INFORMATION 29 March 2023, 07:00 CEST Biocartis To Publish 2022 Annual Report on 11 April 2023 Mechelen, Belgium, 29 March 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it will publish its 2022 annual report on 11 April 2023, which is later than the previously communicated publication date, because the audit of the consolidated financial statements is not finalized w

  • GlobeNewswire

    Press release Biocartis Group NV: Disclosure of transparency notification

    PRESS RELEASE - REGULATED INFORMATION 3 March 2023, 17:40 CET Disclosure of transparency notification Mechelen, Belgium, 3 March 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down miscellaneous prov

  • GlobeNewswire

    Press release Biocartis Group NV: Biocartis announces the US FDA 510(k) clearance for the Idylla™ MSI Test

    PRESS RELEASE 2 March 2023, 7:00 CET BIOCARTIS ANNOUNCES THE US FDA 510(k) CLEARANCE FOR THE IDYLLA™ MSI TEST Mechelen, Belgium, 2 March 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the U.S. Food and Drug Administration (FDA) 510(k) clearance1 for its fully automated Idylla™ MSI Test. This 510(k) clearance reinforces Biocartis’ commitment to enable clinical molecular diagnostics in the U.S. Now,